NCT01860599

Brief Summary

It is well known that diabetes and excessive or high blood sugars causes blood vessel and blood cell damage. It is also possible, then, that people with pre-diabetes may also start to have blood vessel and blood cell damage as the blood sugars rise from the normal range into the diabetic range. In addition to looking at potential damage, the question is whether or not this damage improves with exercise. This study aims to look at blood vessel and blood cells in three different ways by 1) looking at how the blood vessel responds to "sheer force" (a blood pressure cuff pumped up and then released after a few minutes). This is done by ultrasound. 2) By looking at blood tests such as blood sugar, cholesterol, and inflammation and 3) By looking at certain blood cells in the lab, how long they live and the number of cells left after a certain number of days, and again, if this improves with exercise.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2010

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

May 9, 2013

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 23, 2013

Completed
Last Updated

July 17, 2014

Status Verified

July 1, 2014

Enrollment Period

3.2 years

First QC Date

May 9, 2013

Last Update Submit

July 16, 2014

Conditions

Keywords

prediabetesEPC'svascular reactivity

Outcome Measures

Primary Outcomes (1)

  • Measures of Endothelial Function by studying number, function and gene expression of endothelial progenitor cells (identified as CD34+ cells)

    A. Number of viable CD34 +ve cells at Day-0 and viability assay. B. Colony Formation count assay at Day-5, pre and post exercise. C. We will test CD34+ cell migration, adhesion and tube formation properties. D. Gene expression in CD34+ cells of critical endothelial function and inflammatory genes will be measured: eNOS, vWF and PECAM1, VE-cadherin, VEGF-A, Superoxide dismutase (SOD)-1, 2 and 3, Catalase, Interleukin (IL)-6, Tumor Necrosis Factor (TNF alpha), P53, P21, PUMA, Bcl2 \[Apoptosis genes\] will also be noted

    16 weeks per patient

Secondary Outcomes (1)

  • Measures of Vacular Reactivity

    16 weeks

Other Outcomes (1)

  • Measures of Insulin Sensitivity by measuring inflammatory molecules as a surrogate of insulin resistance

    16 weeks

Study Arms (2)

Prediabetes with exercise

OTHER

150 minutes of moderate exercise per week

Behavioral: Exercise

Prediabetes without exercise

OTHER

Pre-study activity level (i.e. no exercise)

Behavioral: Without exercise

Interventions

ExerciseBEHAVIORAL

150 minutes of moderate exercise per week

Prediabetes with exercise

Pre-study activity level (i.e. no exercise)

Prediabetes without exercise

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Prediabetic
  • Impaired fasting glucose (100-125mg/dl)
  • Impaired glucose tolerance (2' post between 140-199mg/dl)
  • HbA1C 5.7-6.4 mg/d (inclusive)
  • Exercise Naive
  • BMI between 20-39.9
  • Nutritional Counseling prior to participation with CDE/RD
  • Willing to wear activity monitor
  • Willing to keep a dietary log

You may not qualify if:

  • Pace maker or other implanted device that might have interference with Tanita scale
  • Any contraindication to moderate exercise
  • Previous coronary disease or cerebrovascular event active or clinically significant coronary vascular disease, or peripheral vascular disease
  • Diabetes
  • Uncontrolled hypertension (SBP \> 140 or DBP \> 90 on 3 separate occasions) ACE's or ARB's
  • Premature familial CAD (Father \< 55years\_\_\_\_ Mother \<65years)
  • HDL \< 40mg/dl
  • Triglycerides \>400mg/dl
  • Any new lipid lowering medication started in the past 6 months
  • Framingham Risk Score two or more
  • Smoking
  • Hypertension (B/P \> 140/90 or on antihypertensives)
  • HDL \< 40mg/dl
  • Age men \>45years or women \>55years
  • Low hematocrit ( or hemoglobinopathies that may impair exercise tolerance) or abnormal CBC
  • +15 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Baystate Medical Center

Springfield, Massachusetts, 01199, United States

Location

MeSH Terms

Conditions

Prediabetic State

Interventions

Exercise

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Sabyasachi Sen, MD, PhD

    Baystate Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor Endocrinology

Study Record Dates

First Submitted

May 9, 2013

First Posted

May 23, 2013

Study Start

March 1, 2010

Primary Completion

May 1, 2013

Study Completion

May 1, 2013

Last Updated

July 17, 2014

Record last verified: 2014-07

Locations